{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:31:09Z","timestamp":1788449469106,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10549-026-07962-0","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:04:06Z","timestamp":1776391446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"217","author":[{"given":"Lorrany Larisse Costa","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"de Holanda Juc\u00e1 Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Felipe C.","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Gonzaga","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbert Oliveira Costa","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Macambira","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Theresa Zuffo","family":"Yabrude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo Garza","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9ia Cristina","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess\u00e9 Lopes","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Batalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"7962_CR1","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Somerfield MR, Barton DL et al (2021) Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol 39:3959\u20133977","journal-title":"J Clin Oncol"},{"key":"7962_CR2","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M et al (2021) Breast cancer. The Lancet 397:1750\u20131769","journal-title":"The Lancet"},{"key":"7962_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102924","volume":"135","author":"TK Sahin","year":"2025","unstructured":"Sahin TK, Rizzo A, Guven DC et al (2025) Post-progression treatment options after CDK4\/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer. Cancer Treat Rev 135:102924","journal-title":"Cancer Treat Rev"},{"key":"7962_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102569","volume":"117","author":"C Corti","year":"2023","unstructured":"Corti C, De Angelis C, Bianchini G et al (2023) Novel endocrine therapies: what is next in estrogen receptor positive, HER2 negative breast cancer? Cancer Treat Rev 117:102569","journal-title":"Cancer Treat Rev"},{"key":"7962_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244179","volume":"16","author":"M Agostini","year":"2024","unstructured":"Agostini M, Mandrioli A, Zamagni C (2024) Fulvestrant monotherapy after CDK4\/6 inhibitors in metastatic breast cancer patients: a real-life experience. Cancers 16:4179","journal-title":"Cancers"},{"key":"7962_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14737159.2019.1631799","volume":"19","author":"M Carausu","year":"2019","unstructured":"Carausu M, Bidard F-C, Callens C et al (2019) ESR1 mutations: a new biomarker in breast cancer. Expert Rev Mol Diagn 19:599\u2013611","journal-title":"Expert Rev Mol Diagn"},{"key":"7962_CR7","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","volume":"25","author":"M Piccart","year":"2014","unstructured":"Piccart M, Hortobagyi GN, Campone M et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25:2357\u20132362","journal-title":"Ann Oncol"},{"key":"7962_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176424","volume":"969","author":"G Guglielmi","year":"2024","unstructured":"Guglielmi G, Del Re M, Gol LS et al (2024) Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer. Eur J Pharmacol 969:176424","journal-title":"Eur J Pharmacol"},{"key":"7962_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115739","volume":"228","author":"C Valenza","year":"2025","unstructured":"Valenza C, Curigliano G (2025) Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer. Eur J Cancer 228:115739","journal-title":"Eur J Cancer"},{"key":"7962_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"F-C Bidard","year":"2025","unstructured":"Bidard F-C, Mayer EL, Park YH et al (2025) First-line Camizestrant for emerging ESR1 -mutated advanced breast cancer. N Engl J Med 393:569\u2013580","journal-title":"N Engl J Med"},{"key":"7962_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/14737140.2025.2479604","volume":"25","author":"TK Sahin","year":"2025","unstructured":"Sahin TK, Aksoy S, Guven DC (2025) Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4\/6 inhibitors. Expert Rev Anticancer Ther 25:471\u2013484","journal-title":"Expert Rev Anticancer Ther"},{"key":"7962_CR12","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. BMJ 2021:n71","journal-title":"BMJ"},{"key":"7962_CR13","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:14898","journal-title":"BMJ"},{"key":"7962_CR14","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","volume":"20","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, Ma C, De Laurentiis M et al (2024) VERITAC-2: a phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer. Future Oncol 20:2447\u20132455","journal-title":"Future Oncol"},{"key":"7962_CR15","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/JCO.22.02746","volume":"41","author":"SM Tolaney","year":"2023","unstructured":"Tolaney SM, Chan A, Petrakova K et al (2023) AMEERA-3: randomized phase II study of amcenestrant (oral selective estrogen receptor degrader) versus standard endocrine monotherapy in estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer. JCO 41:4014\u20134024","journal-title":"JCO"},{"key":"7962_CR16","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1200\/JCO.23.01500","volume":"42","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Lim E, Chavez-MacGregor M et al (2024) Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study. J Clin Oncol 42:2149\u20132160","journal-title":"J Clin Oncol"},{"key":"7962_CR17","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"F-C Bidard","year":"2022","unstructured":"Bidard F-C, Kaklamani VG, Neven P et al (2022) Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: results from the randomized phase III emerald trial. JCO 40:3246\u20133256","journal-title":"JCO"},{"key":"7962_CR18","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","volume":"25","author":"M Oliveira","year":"2024","unstructured":"Oliveira M, Pominchuk D, Nowecki Z et al (2024) Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 25:1424\u20131439","journal-title":"Lancet Oncol"},{"key":"7962_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML et al (2025) Imlunestrant with or without Abemaciclib in advanced breast cancer. N Engl J Med 392:1189\u20131202","journal-title":"N Engl J Med"},{"key":"7962_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-025-01062-6","volume":"22","author":"P Neven","year":"2025","unstructured":"Neven P, Han SN (2025) PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2\u2212 breast cancer harbouring acquired ESR1 mutations. Nat Rev Clin Oncol 22:709\u2013710","journal-title":"Nat Rev Clin Oncol"},{"key":"7962_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10549-024-07595-1","volume":"209","author":"R Scafetta","year":"2025","unstructured":"Scafetta R, Zagami P, Del Re M et al (2025) Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences. Breast Cancer Res Treat 209:455\u2013465","journal-title":"Breast Cancer Res Treat"},{"key":"7962_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2593540","author":"AK G\u00fcren","year":"2025","unstructured":"G\u00fcren AK, Kircali MF, K\u00f6stek O et al (2025) Post-CDK4\/6 inhibitor treatment landscape in metastatic hormone receptor-positive breast cancer: a narrative review. Expert Rev Anticancer Ther. https:\/\/doi.org\/10.1080\/14737140.2025.2593540","journal-title":"Expert Rev Anticancer Ther"},{"key":"7962_CR23","doi-asserted-by":"publisher","first-page":"TPS1119","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1119","volume":"41","author":"EL Mayer","year":"2023","unstructured":"Mayer EL, Tolaney SM, Brufsky A et al (2023) evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2\u2013 LA\/mBC). JCO 41:TPS1119\u2013TPS1119","journal-title":"JCO"},{"key":"7962_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105808","volume":"10","author":"LFC De Almeida","year":"2025","unstructured":"De Almeida LFC, Leite LF, Filho VOC et al (2025) Cyclin-dependent kinase 4\/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study). ESMO Open 10:105808","journal-title":"ESMO Open"},{"key":"7962_CR25","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1002\/cncr.32345","volume":"125","author":"D Dustin","year":"2019","unstructured":"Dustin D, Gu G, Fuqua SAW (2019) ESR1 mutations in breast cancer. Cancer 125:3714\u20133728","journal-title":"Cancer"},{"key":"7962_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett JO, Spring LM, Bardia A et al (2021) ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res 23:85","journal-title":"Breast Cancer Res"},{"key":"7962_CR27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1200\/JCO.23.02112","volume":"42","author":"M Shah","year":"2024","unstructured":"Shah M, Lingam H, Gao X et al (2024) US Food and Drug Administration approval summary: elacestrant for estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative, ESR1 -mutated advanced or metastatic breast cancer. J Clin Oncol 42:1193\u20131201","journal-title":"J Clin Oncol"},{"key":"7962_CR28","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, Ng CKY, Patsouris A et al (2019) Genomic characterization of metastatic breast cancers. Nature 569:560\u2013564","journal-title":"Nature"},{"key":"7962_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G et al (2018) The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34:427-438.e6","journal-title":"Cancer Cell"},{"key":"7962_CR30","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1158\/1078-0432.CCR-20-0224","volume":"26","author":"NC Turner","year":"2020","unstructured":"Turner NC, Swift C, Kilburn L et al (2020) ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials. Clin Cancer Res 26:5172\u20135177","journal-title":"Clin Cancer Res"},{"key":"7962_CR31","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","volume":"2","author":"S Chandarlapaty","year":"2016","unstructured":"Chandarlapaty S, Chen D, He W et al (2016) Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol 2:1310","journal-title":"JAMA Oncol"},{"key":"7962_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/1055-9965.EPI-18-0591","volume":"28","author":"J Xie","year":"2019","unstructured":"Xie J, Xu Z (2019) A population-based study on liver metastases in women with newly diagnosed breast cancer. Cancer Epidemiol Biomarkers Prev 28:283\u2013292","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"7962_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12883-x","volume":"15","author":"M Zhang","year":"2025","unstructured":"Zhang M, Deng H, Hu R et al (2025) Patterns and prognostic implications of distant metastasis in breast cancer based on SEER population data. Sci Rep 15:26717","journal-title":"Sci Rep"},{"key":"7962_CR34","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0959-8049(03)00601-4","volume":"39","author":"G Atalay","year":"2003","unstructured":"Atalay G, Biganzoli L, Renard F et al (2003) Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 39:2439\u20132449","journal-title":"Eur J Cancer"},{"key":"7962_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-016-4066-7","volume":"161","author":"BA Leone","year":"2017","unstructured":"Leone BA, Vallejo CT, Romero AO et al (2017) Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treat 161:537\u2013548","journal-title":"Breast Cancer Res Treat"},{"key":"7962_CR36","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R et al (2024) Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 391:2110\u20132122","journal-title":"N Engl J Med"},{"key":"7962_CR37","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","volume":"30","author":"A Bardia","year":"2024","unstructured":"Bardia A, Cort\u00e9s J, Bidard FC et al (2024) Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups. Clin Cancer Res 30:4299\u20134309","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07962-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07962-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07962-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:30:12Z","timestamp":1784017812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07962-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7962"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07962-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests related to this work. All authors take responsibility for the accuracy and integrity of the data presented and their interpretation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study is a systematic review and meta-analysis of published data and does not involve human participants. Therefore, ethical approval and informed consent were not required. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under registration number (PROSPERO: CRD420251169402).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Consent to participate"}},{"value":"All authors have reviewed and approved the final version of the manuscript and consent to its publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"16"}}